Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 1/2017

01-02-2017 | Adis Drug Evaluation

Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis

Author: Yahiya Y. Syed

Published in: American Journal of Clinical Dermatology | Issue 1/2017

Login to get access

Abstract

Ixekizumab (Taltz®) is a subcutaneously administered, humanized anti-interleukin-17A monoclonal antibody indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy (USA and EU) or phototherapy (USA). In the phase 3 UNCOVER trials in this patient population, ixekizumab was superior to placebo or etanercept in terms of the proportion of patients achieving a ≥75% reduction from baseline in the Psoriasis Area and Severity Index and in those achieving a static Physician Global Assessment score of 0 or 1, after 12 weeks of induction treatment. Clinical responses to ixekizumab were seen as early as week 1. Patients receiving ixekizumab also reported improvements in health-related quality of life, itching, and work productivity. Clinical responses to ixekizumab were sustained during additional 48 weeks of maintenance treatment. Ixekizumab was generally well tolerated and exhibited low immunogenicity in the UNCOVER trials during up to 60 weeks of therapy. Currently available data indicate that ixekizumab is an effective and generally well tolerated treatment option for patients with moderate to severe plaque psoriasis. It has the potential advantage of one maintenance dose for every 4 weeks.
Literature
1.
2.
3.
4.
Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–74.CrossRefPubMed
5.
Nast A, Gisondi P, Ormerod AD, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris—update 2015—short version—EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277–94.CrossRefPubMed
6.
Levin EC, Gupta R, Brown G, et al. Biologic fatigue in psoriasis. J Dermatolog Treat. 2014;25(1):78–82.CrossRefPubMed
7.
Krueger JG, Fretzin S, Suarez-Farinas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145–54.e9.
8.
Canavan TN, Elmets CA, Cantrell WL, et al. Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am J Clin Dermatol. 2016;17(1):33–47.CrossRefPubMed
9.
10.
11.
12.
Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39–50.CrossRefPubMedPubMedCentral
13.
Wang CQ, Suarez-Farinas M, Nograles KE, et al. IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J Invest Dermatol. 2014;134(12):2990–3.CrossRefPubMed
14.
15.
Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–9.CrossRefPubMed
16.
Gordon KB, Leonardi CL, Lebwohl M, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71(6):1176–82.CrossRefPubMed
17.
Papp K, Zhu B, Leonardi C, et al. Impact of baseline characteristics on the efficacy of ixekizumab in patients with moderate to severe psoriasis in a phase 2 study [abstract no. P8118]. J Am Acad Dermatol. 2014;70(5 Suppl 1):AB171.
18.
Edson-Heredia E, Banerjee S, Zhu B, et al. A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. J Eur Acad Dermatol Venereol. 2016;30(5):864–5.CrossRefPubMed
19.
Langley RG, Rich P, Menter A, et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2015;29(9):1763–70.CrossRefPubMed
20.
Rich P, Langley RG, Menter A, et al. Improvement in nail psoriasis in the open-label extension period of a phase 2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis [abstract no. P068]. J Dtsch Dermatol Ges. 2015;13(Suppl 1):135–6.
21.
Armstrong A, Lebwohl M, Zhu B, et al. Effects of ixekizumab treatment on quality of life during 48 weeks of open-label treatment in a phase 2 trial in psoriasis [abstract no. P067]. J Dtsch Dermatol Ges. 2015;13(Suppl 1):135.
22.
Tham LS, Tang CC, Choi SL, et al. Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis. J Clin Pharmacol. 2014;54(10):1117–24.CrossRefPubMed
23.
Zhu B, Edson-Heredia E, Cameron GS, et al. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2013;169(6):1337–41.CrossRefPubMed
24.
Krueger JG, Suarez-Farinas M, Beselin A, et al. Baseline expression of T Cell receptor gamma-V gene family is associated with high levels of response to ixekizumab treatment in psoriasis [abstract no. 182]. J Invest Dermatol. 2015;135(Suppl 2):S32.
25.
Callis Duffin K, Bagel J, Bukhalo M, et al. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). J Eur Acad Dermatol Venereol. 2016. doi:10.​1111/​jdv.​13768.PubMedPubMedCentral
26.
Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–56.CrossRefPubMed
27.
Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–51.CrossRefPubMed
28.
Augustin M, Gordon K, Nikai E, et al. The impact of ixekizumab treatment on health-related quality of life in patients with moderate-to-severe psoriasis: results from UNCOVER-1 [abstract no. P053]. Exp Dermatol. 2016;25(3):E9.
29.
Burkhardt N. Near or complete resolution of psoriasis is associated with greater improvements in itch and health-related quality of life: an analysis from UNCOVER-2, a phase 3 clinical trial of ixekizumab [abstract]. Australas J Dermatol. 2016;57(Suppl 1):41.
30.
Gerdes S, Korman N, Wilhelm S, et al. Efficacy of ixekizumab in patients with plaque psoriasis, with and without previous exposure to biologic therapies: results at weeks 12 and 60 from UNCOVER-1 [abstract no. P052]. Exp Dermatol. 2016;25(3):E9.
31.
Guenther L, Sebastian M, Wu JJ, et al. Impact of ixekizumab treatment on fingernail psoriasis: results from UNCOVER-1 [abstract no. P054]. Exp Dermatol. 2016;25(3):E9–10.
32.
Menter A, Amato D, Duffin KC, et al. Impact of ixekizumab on palmoplantar plaque psoriasis compared to placebo and etanercept: results from UNCOVER 2 [abstract no. 3271]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB253.
33.
Reich K, Dennehy E, Goldblum O, et al. Impact of ixekizumab treatment on scalp psoriasis: results from the UNCOVER-2 trial [abstract no. 2865]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB253.
34.
Spelman L, Rubel D, Brnabic A, et al. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: sub-analysis of the phase 3 UNCOVER trials in patients with baseline PASI >15 [abstract]. Australas J Dermatol. 2016;57(Suppl 1):40–1.
35.
van de Kerkhof P, Guenther L, Gottlieb A, et al. Improvements in fingernail lesions in patients with moderate-to-severe psoriasis treated with ixekizumab versus placebo and etanercept: results from UNCOVER-2 [abstract no. 2345]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB255.
36.
Gottlieb AB, Lacour JP, Korman N, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two phase III randomized studies. J Eur Acad Dermatol Venereol. 2016. doi:10.​1111/​jdv.​13990.
37.
Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148–55.CrossRefPubMed
38.
Kimball AB, Luger T, Gottlieb A, et al. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials. J Am Acad Dermatol. 2016;75(6):1156–61.CrossRefPubMed
39.
Armstrong AW, Lynde CW, McBride SR, et al. Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials. JAMA Dermatol. 2016;152(6):661-9.CrossRefPubMed
40.
Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2016. doi:10.​1111/​1346-8138.​13622.PubMedCentral
41.
Blauvelt A, Ball S, Dey D, et al. Safety profile of patients achieving complete or near complete resolution of moderate-to-severe psoriasis after 12 weeks of etanercept or ixekizumab: integrated analyses from UNCOVER-2 and UNCOVER-3 [abstract no. 2709]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB269.
42.
Griffiths CE, Papp KA, Ball SG, et al. Ixekizumab for psoriasis - authors’ reply. Lancet. 2016;387(10015):226–7.CrossRefPubMed
43.
Blauvelt A, Cameron G, Gordon K, et al. Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis [abstract no. 3232]. J Am Acad Dermatol. 2016;74(5 Suppl 1):AB258.
44.
Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148(1):95–102.CrossRefPubMed
45.
Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.CrossRefPubMed
46.
Callis Duffin K, Bukhalo M, Bobonich MA, et al. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. Med Devices (Auckl). 2016;9:361–9.CrossRefPubMedPubMedCentral
47.
de Carvalho AV, Duquia RP, Horta BL, et al. Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: a systematic review and meta-analysis of randomized clinical trials. Drugs R D. 2016. doi:10.​1007/​s40268-016-0152-x.PubMed
48.
National Institute for Health and Care Excellence. Ixekizumab for treating moderate to severe plaque psoriasis: appraisal consultation document. 2016. https://​www.​nice.​org.​uk. Accessed 20 Dec 2016.
Metadata
Title
Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis
Author
Yahiya Y. Syed
Publication date
01-02-2017
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 1/2017
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-017-0254-4

Other articles of this Issue 1/2017

American Journal of Clinical Dermatology 1/2017 Go to the issue

Review Article

Paraneoplastic Pemphigus and Autoimmune Blistering Diseases Associated with Neoplasm: Characteristics, Diagnosis, Associated Neoplasms, Proposed Pathogenesis, Treatment

Review Article

Cryofibrinogenemia-Induced Cutaneous Ulcers: A Review and Diagnostic Criteria

Review Article

Literature Review of Cosmetic Procedures in Men: Approaches and Techniques are Gender Specific

Evidence-Based Review

Managing Scalp Psoriasis: An Evidence-Based Review

Adis Drug Evaluation

Dapsone 7.5% Gel: A Review in Acne Vulgaris

Review Article

Relapsing Polychondritis: A Review and Guide for the Dermatologist